Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract analysis and drug discovery firm, right now introduced the appointment of Dr. Steve Jenkinson as Vice President, Drug Discovery and Security Evaluation. The US-based appointment represents an vital step within the enlargement of Metrion’s enterprise, pushed by its ion channel discovery capabilities.
Steve shall be answerable for supporting Metrion’s rising shopper base throughout the US, guiding initiatives, and navigating key milestones. He has a powerful background in drug discovery and secondary pharmacology, together with the administration of drug discovery programmes throughout a number of therapeutic areas and phases, starting from goal identification to the nomination of candidates for preclinical improvement.
Steve has spent over 25 years in management positions driving drug discovery initiatives for GSK and Tanabe Analysis Laboratories. He joins Metrion from Pfizer the place, as Senior Director, he established, developed and led the secondary pharmacology and excessive throughput screening workforce. Steve was additionally beforehand co-chair of the IQ DruSafe Secondary Pharmacology working group and a member of the FDA’s HESI Professional-Arrhythmia group. He has accomplished two postdoctoral analysis fellowships, on the Scripps Institute in La Jolla and on the Neurosciences Institute in San Diego, acquired his undergraduate diploma in pharmacology from the College of Glasgow and PhD in molecular pharmacology from the College of Leicester. He additionally accomplished a grasp’s diploma in scientific analysis on the College of California, San Diego.
We’re more than happy to welcome Steve to the Metrion workforce. His background in each drug discovery and security pharmacology shall be pivotal in supporting our purchasers within the US, enhancing Metrion’s scientific management on this key territory.
Dr Andy Southan, Chief Government, Metrion Biosciences
That is an thrilling time for Metrion, I’m delighted to be a part of a service supplier on such a powerful progress trajectory and to be provided the chance to assist and improve the Firm’s providing to its rising US shopper base.
Dr Steve Jenkinson, VP, Drug Discovery and Security Evaluation, Metrion Biosciences
For extra info: https://www.metrionbiosciences.com/
